Over the last decade-plus, the introduction of several key therapies has shaped the management of inflammatory bowel disease.

Drugs like Humira (adalimumab, AbbVie), Remicade (infliximab, Janssen) and Entyvio (vedolizumab, Takeda) have helped patients achieve meaningful endpoints of clinical remission and mucosal healing. They have also helped many patients avoid colectomy, an outcome once much more common before the expansion of the IBD medicine cabinet.

In a study presented at The American College of Gastroenterology Virtual Annual Scientific Meeting, Miguel Regueiro, MD, from Cleveland

Full Article: https://www.healio.com/news/gastroenterology/20201215/emerging-therapies-in-ibd